Technical Documents and Reports

Regulations
Pelaksanaan Paten Oleh Pemerintah Terhadap Obat Antiviral Dan Antiretroviral, Presiden Republik Indonesia
(President Decree of the Republic of Indonesia No. 76 of 2012 About Implementation of the Government of Patent Medicines), 2012
Unofficial English translation

Keputusan Presiden Republik Indonesia Nomor 6 Tahun 2007 (President Decree of the Republic of Indonesia No. 6 Year 2007 Regarding Amendment of President Decree no. 83 Year 2004 Regarding the Exploitation of Patent by The Government on Anti-Retroviral Drugs), 2007

Regulation of the President of the Republic of Indonesia Number 75 Year 2006 (Regulation of the President of the Republic of Indonesia on The National Aids Commission), 2006

Pelaksanaan Paten Oleh Pemerintah Terhadap Obat Obat Anti Retroviral (Government Regulation of the Republic of Indonesia Number 27 Year 2004 Regarding the Procedure of Exploitation of Patent by the Government), 2004

Unofficial English translation

Chapter VII Implementation of Patent by the Government, Indonesia Patent Law as amended by Law No. 14 on August 1, 2001
Unofficial English Translation



Reports
Republic of Indonesia Country Report on the Follow up to the Declaration of Commitment On HIV/AIDS (UNGASS) Reporting Period 2010-2011, Indonesia National AIDS Commission, 2012

The Response to HIV and AIDS in Indonesia 2006-2011: Report on 5 Years Implementation of Presidential Regulation No.75/2006 on the National AIDS Commission, Indonesia National AIDS Commission, 2011


Press Hits and Civil Society Statements


Public Citizen Press Release (October 11, 2012): Indonesian Government Takes Bold Stance to Reduce Costs of AIDS Medications, Potentially Saving Thousands of Lives

Civil society statements

October 22, 2012-Third World Network: Asian countries act to get cheap drugs (links to twnside.org)

October 16, 2012-
Act UP Paris: Indonesia issues a compulsory license on seven HIV and hepatitis B drugs / L'Indonésie émet une licence obligatoire sur sept médicaments contre le VIH/sida et l'hépatite B (links to actupparis.org)


October 12, 2012-
Médecins Sans Frontières (MSF): MSF responds to Indonesia's intent to issue compulsory licenses on 7 medicines (links to msfaccess.org)

October 12, 2012-JOTHI press release: Indonesia Perluas Akses Pengobatan AIDS dan Hepatitis B (Indonesia expands access to HIV and hepatitis B treatments) (links to jothileaders.com) 

English translation


October 11, 2012-
PC statement: Indonesia Licenses Patents for Seven HIV & Hepatitis B Medicines--Precedent-Setting Government Order has Extraordinary Lifesaving Potential

Traducción en español


October 9, 2012
-Indonesia AIDS Coalition: Pelaksanaan Paten oleh Pemerintah obat Antiviral dan Antiretroviral (In Indonesian)


Press Hits

March 26, 2013-Asia Sentinel: Indonesia to override patents for life-saving medicines (links to asiasentinel.com)

October 30, 2012- Interview with Bruce Parnell, Principal Fellow at Burnet Centre for International Health, on the  use of compulsory licenses in Indonesia, on Radio Australia (links to burnet.edu.au)

October 22, 2012-The Star (Malaysia): Measure to make drugs affordable (links to thestar.com.my)


October 19, 2012-Al Jazeera (video): Indonesia allows local HIV drug production (links to aljazeera.com)

October 19, 2012-
The Jakarta Post: Drugs for HIV/AIDS, Hepatitis to be more affordable (links to thejakartapost.com)

October 18, 2012- Tech Dirt: After India, Indonesia Introduces Patent Licenses For Generic Versions of Drugs (links to techdirt.com)

October 17, 2012-Tribun News: Obat ARV Generik Bagian dari Hak Asasi Manusia (links to tribunnews.com)

October 17, 2012- Managing IP: Indonesia targets seven drugs for compulsory licenses (links to managingip.com)

October 16, 2012- Human Rights Blog: Indonesia overrides patents on HIV drugs (links to humanrightslgbt.blogspot.com)

October 15, 2012- Gay Star News: Indonesia overrides patents on HIV drugs (links to gaystarnews.com)

October 15, 2012-PharmaAfrica: Indonesia issues compulsory licenses against seven HIV, hepatitis drugs (links to pharmaafrica.com)

October 15, 2012- Republika Online: Indonesia acts to override patents on HIV drugs (links to en.republika.co.id)

October 13, 2012
- IP Komodo: The start of compulsory licenses in Indonesia (links to ipkomododragon.blogspot.hk)

European Business Chamber of Commerce in Indonesia

October 13, 2012-European AIDS Treatment Group: Indonesia to override patents on HIV/hep B drugs (links to eatg.org)

October 12, 2012- Pharma Times: Indonesia to override patents on HIV/hep B drugs (links to pharmatimes.com)

October 12, 2012-Reuters: Indonesia acts to over-ride patents on HIV drugs (links to uk.reuters.com)

Jakarta Globe
CNBC
Chicago Tribune
MSNBC
FDA News
See other sites that posted the Reuters article

October 12, 2012-
Info Justice: Public Citizen Press Release: Indonesia Licenses Patents for Seven HIV & Hepatitis B Medicines (links to infojustice.org)


October 12, 2012-IHS: Indonesia issues compulsory licenses against HIV, hepatitis drugs (links to ihs.com)

October 12, 2012- U.S. Global Health Policy: Indonesia Issues Order to Override Patents on 7 HIV, Hepatitis Drugs (links to globalhealth.kff.org)

October 11, 2012- Poverty News Blog: Indonesia overrides all patents for HIV drugs (links to povertynewsblog.blogspot.com)

October 11, 2012-Pharmalot: Indonesia Tries To Override Pharma Patents (links to pharmalot.com)

October 11, 2012-The Guardian: Indonesia in bold move to obtain cheap drugs for HIV (links to guardian.co.uk)

October 11, 2012- Y Charts: Pharma's March Into Emerging Markets Hits Yet Another Rough Spot (links to ycharts.com)

September 25, 2012
-Xinhuanet.com: Indonesia assures supply of drug for HIV/AIDs sufferer after donation cut (links to news.xinhuanet.com)

September 24, 2012-
Jakarta Globe: Indonesia's HIV/AIDS Sufferers Call for Domestic Production of Drugs (links to thejakartaglobe.com)

September 20, 2012
-Mindcomm Online: Pemegang Paten Obat Antiviral dan Antiretroviral Dapat Imbalan 0,5% Nilai Jual Netto (links to mindcommonline.com)

September 14, 2012-Sekretariat Kabinet Republik Indonesia: Pemerintah Perluas Paten Jenis Obat Anti HIV/AIDS dan Hepatitis B (links to sektab.go.id)

September 14, 2012-Politik Indonesia: Permerintah Perluas Paten Obat HIV/AIDS dan Hepatitis B (links to politikindonesia.com) (in Indonesian)

September 11, 2012-Jurnal Hukum Internasional: Compulsory License and Public Health Care in Indonesia (links to senandikahukum.com)


Press Hits Archive

Actions in Indonesia


Indonesia Licenses Patents for Seven HIV & Hepatitis B Medicines -- Precedent-Setting Government Order has Extraordinary Lifesaving Potential

Read Full Statement here
Read Presidential order:    Indonesian | English

On September 3, the government of Indonesia took a quiet but exceptionally important step to expand access to medicines and help save and improve lives of people living with HIV/AIDS and hepatitis B.

President Dr. H. Susilo Bambang Yudhoyono signed a decree authorizing government use of patents for seven HIV/AIDS and hepatitis medicines. If implemented to the full, the measure would introduce widespread generic competition and generate potentially massive cost savings in the world's fourth most populous country. The decree licenses patents for a slate of HIV medicines, and may represent the broadest single use of pharmaceutical patent licensing power by a country since the World Trade Organization 1995 Agreement on Trade-Related Aspects of Intellectual Property (WTO's TRIPS). 

Indonesia's action sets a powerful example for other countries and a critical precedent for global public health. The Presidential decree is part of an effort to greatly expand access to newer and more appropriate antiviral and antiretroviral treatments in Indonesia.

The licensed medicines include efavirenz, abacavir, didanosine, lopinavir + ritonavir, tenofovir, tenofovir + emtricitabine, and tenofovir + emtricitabine + efavirenz.  

Congratulations to Sindi Putri, Abdullah Denovan, and their colleagues at ITPC Indonesia, and JOTHI, among other organizations, who have campaigned for second-line treatment and are advancing access in Indonesia.


Further analysis of Indonesia's government use order, the treatment revolution, and compulsory licenses / government use of patents around the world


Licensed Medicines in Indonesia


 

HIV/AIDS and Hepatitis B in Indonesia:
Find statistics on prevalence, treatment, cost of ARV medicines and funding of national initiatives here


    


 Read why access to second-line antiretroviral therapy matters here


 

“Second-line treatment is an essential pillar in the fight against HIV/AIDS, but because of Abbott’s monopoly pricing, Indonesia cannot afford it. This is why we’re proud to take this step together with our friends around the world to stand up for our right to medicines.”

-- Sindi Putri, International Treatment Preparedness Coalition Indonesia


Global Day of Action, November 10, 2011
In Indonesia, Kaletra costs $1000 ppy while in 2010 per capita GDP was $2,946. ITPC Indonesia and other Indonesian civil society groups sent a letter to Abbott requesting an open license, which would enable Indonesia to access affordable generic lopinavir + ritonavir. 

Additionally, the groups met with officials from the Indonesian Ministry of Health to present a letter requesting the government make use of any patents necessary to provide generic lopinavir + ritonavir.

See ITPC Indonesia's letter to the Indonesian Ministry of Health Here (in Indonesian), November 10, 2011

Public Citizen sends a letter to Minister of Health Dr. Endang Rahayu Sedyaningsih, in support of ITPC Indonesia's request for compulsory licensing
, March 20, 2012


Information about the Medicine Patent Pool

Read about the process that led to compulsory licensing in Indonesia in 2004

 

 


 




Return to the Kaletra Campaign Homepage


Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.